Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Invasion Phenotypes of Oral Squamous Cell Carcinoma

Etemad-Moghadam, Shahroo DDS, MS; Alaeddini, Mojgan DDS, MS

Applied Immunohistochemistry & Molecular Morphology: September 2015 - Volume 23 - Issue 8 - p e12–e16
doi: 10.1097/PAI.0000000000000184
Research Articles

The invasion signature of tumor cells can strongly affect their metastatic behavior; therefore, we aimed to evaluate the different invasion phenotypes of oral squamous cell carcinoma (OSCC) and to determine the correlation of these markers with neoplastic mode of invasion. A total of 92 OSCCs were graded according to the Yamamoto criteria and subjected to immunohistochemistry using monoclonal antibodies against E-cadherin, N-cadherin, and podoplanin. Samples were grouped into epithelial-mesenchymal transition (EMT), collective-cell invasion (CCI), and combined intermediate phenotypes followed by statistical analysis. Significant differences were found among the 3 groups (P<0.001), between EMT and CCI (P=0.023) and between the combined phenotypes and both EMT and CCI, separately (P<0.001). Mode of invasion was significantly associated with E-cadherin (P=0.022), but not the other markers. There seems to be a preference for OSCCs to migrate by CCI; however, most our samples showed an intermediate phenotype between EMT and CCI, which confirm the existence of a spectrum of migration signatures that need to be further evaluated in these tumors.

Dental Research Centre, Dental Research Institute, Dental Research Centre, Tehran University of Medical Sciences, Tehran, Iran

S.EM and M.A. contributed equally.

Supported by a grant from Tehran University of Medical Sciences: grant no. 132/297.

The authors declare no conflict of interest.

Reprints: Mojgan Alaeddini, DDS, MS, Dental Research Institute, Dental Research Centre, Ghods St, Enghelab Ave, P.O. Box: 14155-5583; Tehran 14174, Iran (e-mail:

Received December 27, 2014

Accepted January 15, 2015

Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved.